Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrie

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrie

Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.31) per share which beat the analyst

(Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the s

US stocks down, Dow falls 300+ points, S&P 500 drops 0.93%, Nasdaq falls 1.25%. Energy shares up

Five Below Inc (FIVE) shares rose 7.2% in pre-market trading after reporting better-than-expected Q4

Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million priv

- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 mill

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort

META: 10% | Meta Platforms shares are trading higher after the company reported better-than-expected

Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252,

Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage b

Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage b

– Company addresses FDA requests regarding formulation excipient – Global site start-up activities c

Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.45) per share which beat the analyst

erina expects to receive the FDA's formal clinical-hold letter within 30 days and will provide a

Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company deve

Item 1.01 Entry into a Material Definitive Agreement On September 9, 2025, Serina Therapeutics, Inc.